OPKO Health (OPK) Reports Next Week: Wall Street Expects Earnings Growth
Zacks · 1h ago
Opko Health Rolls Out Multiplex COVID-19, Influenza A/B Test
Opko Health’s subsidiary BioReference Laboratories has launched a new multiplex test that will aid healthcare providers, clinics and health systems in the diagnosis of COVID-19 and Influenza A or B flu.This new test identifies COVID-19 and influenza infections with a single sample. Opko Health (OPK) said that the multiplex test allows for more rapid diagnosis, conserves critical testing supplies, and provides surveillance for flu and COVID-19.Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories stated “Patient care is at the center of our test offering and this multiplex test allows for healthcare providers to differentiate between COVID-19 and influenza by swabbing a patient one time.”Earlier this month, the company announced that BioReference Laboratories has started its COVID-19 testing program for New York City public schools as part of a strategic collaboration with New York City, the Department of Health, New York City Health and Hospital Corporation, the Test & Trace Corp, and the Department of Education. (See OPK stock analysis on TipRanks)Last month, Barrington Research analyst Michael Petusky reiterated a Buy rating for Opko Health with a price target of $7 following a virtual meeting with the company's CFO Adam Logal and Executive Vice President Steve Rubin. From the update provided by the management, the analyst gathered that the company’s lab business has significantly benefited from its ability to land COVID‐19 related PCR (polymerase chain reaction) and antibody serology testing agreements since the crisis began to impact the US.The Street is very bullish about Opko Health and has a Strong Buy consensus based on 4 unanimous Buys. Shares have risen a whopping 203% so far in 2020 and the average analyst price target of $8 implies an upside potential of about 80% over the coming months.Related News: Xeris Wins FDA Fast Track Path For Epilepsy Treatment; Shares Spike 9% AbbVie Submits US, EU Rinvoq Applications For Atopic Dermatitis Pfizer Targets FDA Approval For Covid-19 Vaccine In November; Shares Rise More recent articles from Smarter Analyst: * BD’s Covid-19-Flu Combo Test Wins European Clearance * KeyCorp’s Profit Rises As Credit Loss Provisions Drop 20% * Telia Inks 5G Network Deals With Ericsson, Nokia * Prologis' 2020 Outlook Tops Estimates; Street Says Buy
SmarterAnalyst · 1d ago
Opko's BioReference Labs launches COVID-19/flu combo test
OPKO Health (OPK) unit BioReference Laboratories announces the availability of its multiplex test for COVID-19 and influenza A or B that can differentiate the two infections from a single nasal
Seekingalpha · 2d ago
OPKO Health's BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), is now accepting specimens for a new multiplex COVID-19 and influenza test for use by healthcare providers, clinics and health systems throughout the
Benzinga · 2d ago
Pounding The Table For Undervalued OPKO Health
Rayaldee EU Approval is close and the clinical trial as a COVID therapeutic is underway.Pipeline star Somatrogon, the weekly human growth hormone drug, prepares for FDA BLA submission with partner Pfizer.BioReference Labs continues to impress.
Seekingalpha · 5d ago
OPKO Health, Inc.'s (NASDAQ:OPK) Has Found A Path To Profitability
We feel now is a pretty good time to analyse OPKO Health, Inc.'s (NASDAQ:OPK) business as it appears the company may...
Simply Wall St. · 10/14 15:04
OPKO Health to Report Third Quarter 2020 Financial Results on October 29, 2020
MIAMI, Oct. 13, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 29, 2020. OPKO’s senior management will provide a business update and discuss results in greater detail during a conference call and live audio webcast on October 29th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATIONOPKO encourages participants to pre-register for the conference call using the link here or dialing (888) 869-1189 or (706) 643-5902 and using conference ID 4542807. Upon registering, participants will receive dial-in numbers, an event passcode and a unique registrant ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the start of the call.To access the live call via webcast, please click on the link OPKO 3Q20 Results Conference Call. Individual investors and investment community professionals who do not plan to ask a question during the call’s Q&A session are encouraged to listen to the call via the webcast.For those unable to listen to the live conference call, a replay can be accessed for a period of time on OPKO’s website at OPKO 3Q20 Results Conference Call. A telephone replay will be available beginning approximately two hours after the close of the conference call. To access the replay, please dial (855) 859-2056 or (404) 537-3406, and use conference ID 4542807.About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit Investor Relations Yvonne Briggs, 310-691-7100 or Bruce Voss, 310-691-7100
GlobeNewswire · 10/13 16:51
Opko’s BioReference Lab Begins Covid-19 Testing At NYC Schools
BioReference Laboratories, a wholly-owned subsidiary of Opko Health, has commenced its COVID-19 testing program for New York City public schools. The testing will be conducted throughout the 2020-2021 school year.The COVID-19 molecular testing program being conducted by Opko’s (OPK) BioReference Laboratories for NYC schools is part of a strategic collaboration with New York City, the Department of Health, New York City Health and Hospital Corporation, the Test & Trace Corp, and the Department of Education.Aside from COVID-19 testing, Opko stated that BioReference is also collecting specimens from principals, teachers, administration and students from over 950 schools across NYC.On Sept. 15, OPKO Health announced that it initiated a Phase 2 trial of Rayaldee as a treatment for mild-to-moderate COVID-19. The company stated that the trial will be conducted at multiple COVID-19 outpatient clinics in the US and it expects to report topline results from this Phase 2 trial before the end of this year. (See OPK stock analysis on TipRanks)Last month, Barrington analyst Michael Petusky reiterated a Buy rating for Opko Health with a price target of $7, saying, “OPKO’s lab business has greatly benefitted from its ability to land COVID‐19 related PCR [polymerase chain reaction] and antibody serology testing agreements since the crisis began to impact the U.S. in Q1.”“To date, the company has provided COVID‐19 testing to the general public through its relationships with several states and cities, has signed major partnerships with Rite Aid and CVS, and also has secured several high profile deals with major sports organizations including the NFL, the NBA and Major League Soccer.”Indeed, analysts are unanimously bullish on Opko Health. The Street’s Strong Buy consensus is based on 4 recent Buys. The stock has surged by a stellar 214% year-to-date and the average analyst price target of $8 indicates a further upside potential of 73% from the current levels.Related News: Pfizer, BioNTech Initiate Rolling Canada Submission For Covid-19 Vaccine BioNTech, Rentschler Partner For Covid-19 Vaccine Manufacturing Gilead Inks EU Supply Deal For 500,000 Remdesivir Doses More recent articles from Smarter Analyst: * Daimler, Swiss Re Form Mobility Insurance JV; Goldman Double Upgrades To Buy * GM China 3Q Vehicle Sales Jump 12%; Merrill Lynch Sees 87% Upside * Wix Teams Up With Vodafone For UK Expansion; Shares Now Up 138% YTD * J&J;’s Tremfya Study Shows Improvement In Crohn’s Disease Patients
SmarterAnalyst · 10/12 10:06
OPKO Health's BioReference Labs launches COVID-19 testing program for NYC schools
OPKO Health's (OPK) unit BioReference Laboratories, has commenced its COVID-19 testing program for New York City schools throughout the 2020-2021 school year.Under a collaboration with New York City, the Department of Health, New York City Health
Seekingalpha · 10/09 12:43
OPKO's BioReference Labs Highlights Launch Of COVID-19 Testing Program For New York City Schools Throughout 2020-2021 School Year
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school environment.
Benzinga · 10/09 12:01
Opko Health Successfully Tests a Bottom and Is Ready to Rise
Opko Health (OPK) shares have successfully tested a bottom and a new uptrend in the provider of Covid-19 tests is underway after the correction....OPK · 10/08 12:55
Pfizer's somatrogon successful in pivotal growth hormone deficiency study
Pfizer (PFE) and collaboration partner OPKO Health (OPK) announce positive results from a Phase 3 clinical trial evaluating weekly injections of somatrogon compared to daily injections of Genotropin (somatropin) in
Seekingalpha · 10/08 11:30
Pfizer And OPKO Announced The Phase 3 Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency Met Its Primary Endpoint Of Improved Treatment Burden
Benzinga · 10/08 10:52
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
Investor confidence is high on OPKO Health (OPK), thanks to solid prospects.
Zacks · 10/05 13:41
3 “Strong Buy” Healthcare Stocks Under $5 That Could Go Boom
Since 2019, the healthcare sector has been bracing for the wild ride that would be the election year. However, according to some Street pros, 2021 is looking a lot like 2009, and this could actually be a good thing for the space.“[We] think 2021 will play out very similarly to 2009 for the health care
TipRanks · 10/01 19:30
Implied Volatility Surging for OPKO (OPK) Stock Options
Investors need to pay close attention to OPKO (OPK) stock based on the movements in the options market lately.
Zacks · 09/30 13:43
OPKO Health Initiates Mid-Stage Study on Coronavirus Therapy
OPKO Health (OPK) is developing its marketed drug, Rayaldee, as a potential treatment for patients with mild-to-moderate COVID-19.
Zacks · 09/16 14:25
Opko Launches Phase 2 Trial Of Covid Treatment Rayaldee; Street Bullish
Opko Health announced the initiation of a Phase 2 trial of Rayaldee as a treatment for mild-to-moderate COVID-19. After rising in the pre-market trading hours, Opko stock was down 0.63% at the close on Tuesday.Opko Health’s (OPK) Rayaldee is an extended-release oral formulation of calcifediol, a prohormone
SmarterAnalyst · 09/16 09:48
OPKO Health (OPK) Stock Sinks As Market Gains: What You Should Know
OPKO Health (OPK) closed at $3.15 in the latest trading session, marking a -0.63% move from the prior day.
Zacks · 09/15 21:45
Opko Shares Climb on Phase 2 Trial of Coronavirus Treatment
Opko plans to enroll about 160 people in a Phase 2 double-blind trial of a coronavirus treatment candidate. · 09/15 14:05
Webull provides a variety of real-time OPK stock news. You can receive the latest news about OPKO Health through multiple platforms. This information may help you make smarter investment decisions.
About OPK
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.